Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
MMF in IgA: Inching into the MAINstream?
Mycophenolate in IgAN - The Visual Abstract
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan
Day 3 : yet another IgA trial, and we are back with some flozin news: in ADPKD, their effect on hemoglobin, and on BP (with finerenone)
Day 2 was less exciting: we cover 1 IgA trial (Ravulizumab) along with another calcimimetic, and a pentoxifylline meta-analysis.
Day of Kidney Week 2026. The NephJC crew discusses 6 studies, including some blockbustr IgA news.
This week, we will discuss whether decreased donor transplantation improves mortality in all patients. In this target trial emulation standard donor, extended donor, donation after brain death and donation after cardiac death outcomes are compared across age groups with different co-morbid conditions.
Check out the tweetorial for the MAIN event - does MMF work in IgA Nephropathy?
Welcome to #TenTweetNephJC!
— Nephrology Journal Club (@NephJC) April 28, 2023
✳️10 tweets #NephJC catch-up ✳️
On 3/28-29, #NephJC reviewed the MAIN trial (Mycophenolate monotherapy in IgA Nephropathy). Here are some pearls from the chat ⬇️ pic.twitter.com/RUepFSEwXx
Visual abstract for utility of MMF in IgAN by NSMC intern Dr Jeyakumar Meyyappan